Polaryx Therapeutics, Inc.
PLYXNasdaqCIK 2075320HealthcareFiscal year ends Dec 31
Reports and events: 13 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-1419:59 ET | 8-K | 5.07 Shareholder vote results | 0001213900-26-099416 |
| 2026-09-0116:30 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-096235 |
| 2026-08-1316:15 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001213900-26-089118 |
| 2026-07-2817:00 ET | DEF 14A | Proxy statementPeriod 2026-09-10 | 0001213900-26-082339 |
| 2026-07-2116:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001213900-26-080041 |
| 2026-07-1708:00 ET | 8-K | 5.08 Item not in the standard list; 8.01 Other events | 0001213900-26-078912 |
| 2026-05-2816:31 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-062155 |
| 2026-05-1520:01 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001213900-26-056973 |
| 2026-03-2417:48 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001213900-26-033064 |
| 2026-02-0516:05 ET | SCHEDULE 13D | Ownership report, active investor | 0001213900-26-012759 |
| 2026-01-2708:02 ET | S-1/A | Registration statement, amended | 0001213900-26-007973 |
| 2026-01-1419:30 ET | S-1/A | Registration statement, amended | 0001213900-26-004079 |
| 2025-11-2119:16 ET | S-1 | Registration statement | 0001213900-25-113249 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.